RNA interference (RNAi) gene silencing is a potential therapeutic strategy for dominant retinal degeneration disorders. We used self-complementary (sc) AAV2/8 vector to develop an RNAi-based gene therapy in a dominant retinal degeneration mouse model expressing bovine GCAP1(Y99C). We established an in vitro shRNA screening assay based on EGFP-tagged bovine GCAP1, and identified a shRNA that effectively silenced the bovine GCAP1 transgene with ∼80% efficiency. Subretinal injection of scAAV2/8 carrying shRNA expression cassette showed robust expression as early as 1 wk after injection. The gene silencing significantly improved photoreceptor survival, delayed disease onset, and increased visual function. Our results provide a promising strategy toward effective RNAi-based gene therapy by scAAV2/8 delivery for dominant retinal diseases.
H ereditary retinal dystrophies, characterized by loss of visual function, are a genetically and phenotypically heterogeneous group of retinal degenerations with a prevalence of 1 in 3,000 (1) . Approximately 30% of these dystrophies are inherited in an autosomal-dominant fashion (RetNet database: http://www. sph.uth.tmc.edu/retnet/sum-dis.htm), caused by gain-of-function mutant alleles producing gene products with dominant negative or abnormal functions. Allele-specific RNA interference (RNAi) has become a potent therapeutic strategy for dominantly inherited disorders (2) , exceeding other existing gene silencers, such as ribozyme and antisense oligonucleotides (3, 4) in specificity and efficiency. Using siRNA and shRNA, promising results were reported in clinical and preclinical studies on dominantly inherited amyotrophic lateral sclerosis, spinocerebellar ataxia, Huntington disease, and other nucleotide repeat diseases (2, 5, 6) . Ocular diseases, such as dominant retinitis pigmentosa (RP) and age-related macular degeneration (AMD), have been regarded as ideal targets in the development of gene therapies, as the eye is easily accessible for therapeutic intervention (7) . RNAi studies not requiring resistant replacement include knockdown of VEGF and its receptor in wet AMD (8, 9) . However, for lack of specificity and side effects via activation of the Toll-like receptor 3 (10) , some clinical studies (e.g., bevasiranip, a synthetic siRNA to treat macular degeneration) have been terminated (11) . In contrast, shRNA silencing of the Rhodopsin disease allele using recombinant AAV2/5 vectors provided significant therapeutic benefit for both retinal structure and function in dominant RP mouse models (12) (13) (14) . Further, recombinant AAV2/8 vectors expressing miRNA and shRNA can effectively knock down peripherin-2 in mouse photoreceptors without apparent "offtarget" effects (15) .
Mutations in the human GUCA1A gene expressing the Ca 2+ -binding protein GCAP1 are associated with autosomal dominant cone dystrophy (adCD), dominant cone/rod dystrophy (adCORD), and macular dystrophy in several unrelated families (16) (17) (18) . These diseases are slowly progressing and characterized by photophobia, loss of color vision, and reduced central visual acuity (19) . We set out to test the therapeutic efficacy of RNA interference in two transgenic mouse lines expressing a mutant bovine GCAP1 [bGCAP1(Y99C)] (20) . These lines are models for dominant rod/cone dystrophy (retinitis pigmentosa) representing severe (line L53) and moderate (line L52H) retinal degeneration phenotypes (20) . We reasoned that specific shRNAs directed against mutant bovine Guca1a mRNA would suppress expression of the mutant GCAP1 protein that produces the dominant gain-of-function effect, but without effect on its mouse ortholog. If successful, knockdown of mutant bovine GCAP1 would significantly delay onset and progression of dominant photoreceptor dystrophy in the mouse model.
Here we report efficiencies of shRNA-mediated gene therapy in two GCAP1(Y99C) transgenic mouse lines. We first established an in vitro shRNA screening system to identify an efficient anti-bGCAP1 shRNA, and then show that scAAV2/8-mediated delivery of the most potent shRNA could suppress expression of the mutant GCAP1 in photoreceptors up to 1 y postinjection. Silencing of the dominant-negative transgene significantly improved retinal morphology and function relative to the contralateral, control eye.
Results
Identification of Effective shRNAs Targeting GCAP1 in Vitro. By modifying the vector mU6pro (21), we generated a shRNA expression vector, hH1pro, in which the human H1 pol-III promoter drives shRNA expression (Fig. 1A) . In this vector, the shRNA expression cassette, consisting of a 68-bp sense-loopantisense hairpin and a transcription termination signal (Tts), is linked to a CMV-driven mCherry reporter gene in a tail-to-tail array (Fig. 1B) . We generated four shRNA constructs, hp1-4, expressing four anti-bGCAP1 shRNAs specifically targeting bovine Guca1a mRNA at positions (starting from ATG) 53-73, 160-180, 273-293, and 409-429 (Fig. 1C) . To screen for bGCAP1 knockdown in vitro, we cotransfected transiently plasmids of each construct with EGFP-tagged bGCAP1 expression plasmids (bGCAP1-EGFP) into HEK293 cells at a 3:1 ratio (Fig.  1D ). Live-cell fluorescence imaging and immunoblotting were performed at 48-50 h posttransfection to analyze bGCAP1 silencing. Fluorescence microscopy revealed that hp1-4 transfected HEK293 cells similarly, as reported by mCherry signal (Fig. 1D, Lower) . However, fluorescence intensities of bGCAP1-GFP in the cotransfected cells decreased variably, demonstrating a silencing effect (Fig. 1D, Upper) . The shRNA hp4 showed the highest knockdown efficiency, as indicated by low GFP fluorescence in the cotransfected cells (Fig. 1D) . Semiquantitative Western blotting ( Fig. 1 E and F) revealed that hp1-4 reduced bGCAP1 expression in the cotransfected cells by 68%, 47%, 58%, and 79%, respectively.
Sequence Specificity and Dose Dependency of Guca1a RNA Knockdown. To verify the sequence specificity of hp4-mediated bGCAP1 silencing, we generated a two-nucleotide mismatch shRNA control, hp4m2, by mutating two central nucleotides in the hp4 guide strand (Fig. 1C) . Plasmids encoding hp4 or hp4m2 were cotransfected into HEK293 cells with bGCAP1-EGFP plasmids at five different ratios of hp4 or hp4m2/bGCAP1-EGFP (1:3, 1:2, 1:1, 2:1, and 3:1; Fig. 2 ). At 48-50 h posttransfection, mRNA and protein levels were analyzed by live-cell fluorescence imaging ( Fig. 2A) , real-time RT-PCR (Fig. 2B) , and Western blot ( Fig. 2 C and D) . Fluorescence imaging showed that expression levels of bGCAP1-EGFP were incrementally reduced with increasing amounts of the hp4 expression plasmid. No apparent silencing was observed in the cotransfected cells expressing the mismatch control hp4m2 at all five ratios ( Fig. 2A, Lower). Quantitative RT-PCR confirmed that bGCAP1 mRNA levels were reduced sequentially, from 41% at the lowest ratio (1:3) to 85% at the highest hp4:bGCAP1 ratio (3:1; Fig. 2B ). Immunoblot assay showed that expression of bGCAP1 in the cotransfected cells decreased correspondingly from 78% to 23% (Fig. 2 C and D) . By contrast, no significant change of bGCAP1 mRNA or protein level was observed in the h4m2/bGCAP1 cotransfected cells (Fig. 2 B-D hp4 suppressed bGCAP1-EGFP efficiently at both mRNA and protein levels in a sequence-and dose-dependent manner, indicating that suppression is mediated through the RNA interference pathway.
Long-Term Expression of hp4 by scAAV2/8 Viral Vectors in Mouse
Retina. Self-complementary (sc), recombinant AAV vectors (scAAVs) show rapid, sustained, and highly effective transgene expression in various tissues, including photoreceptors (22) (23) (24) . However, to date, these vectors had not been used for shRNA expression. We selected a pseudotyped scAAV2/8 viral vector with photoreceptor/retinal pigment epithelial (RPE) tropism to deliver hp4 and its mismatch control to mouse photoreceptors. The hp4 and hp4m2 expression constructs were packaged into scAAV2/8 viral vectors, thereby generating scAAVhp4 and scAAVhp4m2 viral particles (Fig. S1 ). To determine transduction efficiency and durability of the viral particles, scAAVhp4 was injected into the subretinal space of P21 wild-type mice. We performed in vivo fluorescence imaging of injected eyes and confocal microscopy of transverse retinal cryosections to assess expression of hp4, evidenced by the mCherry reporter, at times ranging from 1 wk to 1 y postinjection. The mCherry reporter was expressed robustly and broadly in wild-type retinas at 1 wk and maintained a maximum level for 1-4 mo (Fig. S1 ). Expression decreased slightly after 4 mo, but remained strong even 1 y postinjection (Fig. S1B) . Corresponding frozen sections of transduced retinas showed that hp4 was present in virtually all photoreceptors (Fig. S1B, Lower) . The early onset, sustained duration, and broad photoreceptor distribution of the mCherry reporter indicate that scAAV2/8 is an excellent shRNA expression vector for long-term gene silencing in photoreceptors.
Photoreceptor Degeneration Is Delayed in L53 and L52H Transgenic
Mice After shRNA Treatment. We first tested the specificity of shRNA silencing in L52H transgenic mice that overexpress mutant bovine GCAP1(Y99C) slightly, i.e., 1-2 bovine GCAP1 per endogenous mouse GCAP1, estimated from immunoblot intensity (20) . ScAAVhp4 or hp4m2 (control) viral particles were injected into the subretinal space of L52H mice at P21. Transduced eyes with detectable mCherry fluorescence across >50% of retina area at 5 d postinjection were harvested 30 d later.
Immunoblots of scAAVhp4-treated retinas (Fig. 3A, lanes 1 and  2) show decreased levels of mutant bovine GCAP1 while maintaining normal levels of endogenous mouse GCAP1. Retinas injected with scAAVhp4m2 mismatch control viral particles reveal a bGCAP1 level similar to that of the noninjected control (Fig. 3A, lanes 3 and 4) . Consequently, scAAVhp4 appears to target the bovine GCAP1(Y99C) allele specifically. We next examined whether scAAV2/8-mediated hp4 expression could produce a therapeutic effect. L53 mice overexpress transgenic bGCAP1(Y99C) at levels 3-4× that of endogenous mouse GCAP1, and develop rapidly progressing retinal degeneration (20) . By P17, photoreceptor outer segments are absent and the outer nuclear layer (ONL) appears in disarray (Fig. S2) . We injected scAAVhp4 subretinally in L53 mouse eyes at P12, the day of eye-opening and when degeneration just begins. Transverse retinal cryosections of successfully transduced eyes (n = 5 at each time point) were examined by confocal microscopy at 30 and 45 d postinjection. Encouragingly, scAAVhp4-treated retinas revealed 6-7 rows of photoreceptor nuclei surviving in the ONL, whereas untreated retinas had only four remaining rows of photoreceptor nuclei at 42 d, and two rows at 57 d (Fig. 3B) . Thus, scAAV2/8-mediated hp4 expression clearly promoted survival of photoreceptors in a severe and rapid RP model. Therapeutic benefit of hp4 expression was also examined in L52H transgenic mice. The L52H mouse line offers an extended window for RNAi treatment owing to lower mutant protein expression and delayed onset of cell death (starting ∼2 mo postnatally). Either scAAVhp4 or its mismatch control were injected subretinally into cohorts of five predegenerate L52H left eyes (P21-P30), which were analyzed over subsequent months (1, 2, 4, 8, and 11 mo). Mutant mice treated with scAAVhp4 showed delayed degeneration, maintaining 10-12 rows of nuclei at 2 mo, slowly decreasing to 8-9 rows at 4-6 mo, and to 4-6 rows at 11 mo postinjection (Fig. 3C, Left) . Although no morphological differences between treated and untreated transgenic retinas could be discerned at 1 mo postinjection, beginning at 2 mo and thereafter, untreated eyes or eyes treated with the mismatch control, scAAVhp4m2, revealed photoreceptor degeneration progressing with time to only one to two rows of nuclei at 11 mo (Fig. 3C , Center and Right). Suppression of mutant bGCAP1(Y99C) expression via shRNA-mediated RNAi appeared to delay the rate of photoreceptor degeneration.
Visual Function Is Maintained in scAAVhp4-Treated Transgenic Mice.
Electroretinograms (ERG) and behavioral tests (OptoMotry) are noninvasive tests of visual function. We observed no significant difference in ERG and OptoMotry responses between untreated and mismatch-treated L52H mouse eyes over the course of 10 mo (Fig. 4 A-C) . In scotopic ERG, the a-wave amplitudes from untreated or scAAVh4m2-treated eyes decreased slowly and nearly linearly (Fig. 4A and Table S1 ). However, scAAVhp4-treated eyes exhibited robust scotopic awave responses even at 10 mo postinjection, suggesting significant therapeutic benefit of RNAi treatment. Progressive dysfunction of L52H cones was much slower than that of rods, consistent with a retinitis pigmentosa phenotype. No significant differences in photopic ERG responses between treated and untreated eyes were recognizable in the first 3 mo postinjection ( Fig. 4B and Table S1 ). The average b-wave amplitudes of photopic ERG responses of treated L52H eyes were relatively steady until 6 mo postinjection, whereas untreated and mismatch treated eyes showed slightly diminished responses. Visual acuities of the treated and untreated mouse eyes (8-10 eyes, each type at each time point) were analyzed by a virtual OptoMotry system at different time points from 0 to 10 mo postinjection. Visual acuity of treated L52H mouse eyes was unchanged for 6 mo postinjection, and dropped off at 7 and 10 mo (Fig. 4C and Table S2 ). Average visual acuity of 8-10 treated eyes decreased slowly until about 6 mo postinjection, and then degraded more strongly as scAAVhp4 expression slowly decreased. The significant improvement of photopic visual acuity in treated eyes is consistent with photopic ERG results.
Discussion
We tested whether scAAV2/8, packaging a shRNA expression cassette including a reporter gene, could provide both on-target gene silencing and durability of expression in vivo, attributes required for eventual human gene therapy. We developed an in vitro shRNA screening assay with double-fluorescence reporters to compare shRNA efficacies (Fig. 2) . This universally applicable assay relies on the diminishing fluorescence of the fusion protein whose RNA is degraded by the RNAi. Once identified, the most effective shRNA cassette (hp4) was packaged into viral particles and injected into the subretinal space of bGCAP1(Y99C) transgenic mice at predegenerate time points. We selected recombinant AAV vectors because they transduce efficiently, remain generally episomal, have sufficient packaging capacity for shRNA expression, and cause no obvious adverse side effects (25) . Compared with single-stranded rAAV2/8 vectors, the most recently developed self-complementary AAV2/8 vector, generated by packaging a self-complementary transgene flanked by AAV serotype 2 inverted terminal repeats (ITRs) within a serotype 8 capsid, is much improved in specificity, stability, and kinetics of transgene expression in photoreceptors (22) (23) (24) . Our results show that the scAAV2/8 vector could express shRNA in photoreceptors as early as 1 wk (Fig. S1B) , and that expression persisted at high levels for 1 y. Beneficial effects were seen in the rapidly progressing L53 line (Fig. 3B) as early as 1 mo postinjection. In the moderate retinal degeneration mouse model L52H, retinal morphology and function were sustained for as long as 10 mo postinjection (Figs. 3C and 4) .
The eye is a compartmentalized and relatively isolated organ. ScAAVhp4 or hp4m2 (mismatch control) viral particles were injected into the subretinal space of L52H mice at P21-P30 and followed for up to 1 y. Encouragingly, ∼80% knockdown of the mutant allele achieved using ScAAVhp4 provided a significant, long-term improvement in retinal morphology, ERG, and OptoMotry measurements. Though the mismatch control virus, scAAVhp4m2, failed to provide a therapeutic effect, it also did not exacerbate the ongoing degeneration. Studies in rodent, dog, and primate reveal that ocularly delivered AAV does not spread widely outside the injected eye, with optic nerve and brain as exceptions (26) . As viral vectors are lost with time distal from the site of administration (27) , virus with retina/RPE tropism would be increasingly restricted with time. The sustained (up to 1 y) preservation of retina morphology and function with scAAVhp4 suggests little, if any, off-target shRNA interference that is usually accompanied by increased cell death or inactivation of the virus by induction of the antiviral IFN pathway machinery (28) . The Y99C missense mutation in GCAP1 was originally detected in a four-generation British family (29) , and independently in two ancestrally related families (30 (31, 32) , which results in persistent enzymatic activity in the dark, causing a rise in cGMP and Ca 2+ and ultimately leading to photoreceptor cell death (33) . In young CORD patients, rod and cone ERGs are often near normal, and thereafter, cone ERGs decline progressively. Slow disease progression implies an extended window during which effective shRNA-expressing virus may be applied. To date, eight unique disease-associated GUCA1A mutations are known, affecting more than two dozen families worldwide (Fig.  S3 Lower) . For two of these mutations, Y99C (29) and E155G (18, 34) , it has been demonstrated that delay of retinal degeneration in mouse models would require a permanent activation of cGMP hydrolysis (33, 35) . Our alternate strategy simply removes most mutant protein responsible for the dominantnegative effect by Guca1a RNA knockdown. Importantly, the knockdown strategy is applicable to all GCAP1 mutations as long as the guide strand of shRNA is located outside hands EF3 and EF4 that contain the disease-causing mutations.
Our results show that hp4 is allele specific (on target), knocking down only the mutant transgene (Fig. 3A) . Because the GCAP1 mutant allele in human patients would likely differ from its wild-type counterpart by a single base substitution, an allelespecific shRNA degrading the mutant RNA cannot be generated. However, a non-allele-specific GCAP1 shRNA may be used to target both mutant and wild-type Guca1a alleles in a practical RNAi gene therapy approach. Because deletion of the GCAP genes in mouse had no detectable retina degeneration consequence (36, 37) , knockdown of both dominant mutant and wild-type Guca1a RNA species may suppress the disease phenotypes without pathology. Physiologically, deletion of both mouse GCAPs resulted in increased sensitivity of the rod photoresponse, increased amplitude of the single photon response, slowed recovery kinetics, and a delay in photoreceptor recovery (36) (37) (38) (39) . In mouse rods, however, GCAP1 absence can be mitigated partially by the second GCAP homolog (GCAP2), which contributes to the recovery kinetics and light adaptation, and can nearly restore the normal response to bright flashes (36, 40) . Extrapolation of consequences of GCAP knockout in mouse to human GUCA1A −/− patients clearly is speculative. However, knocking down GCAP1 in human rods would be predicted to have no major deleterious effect on human dim light (scotopic) vision as human rods express GCAP2 as well (41) . Moreover, a third GCAP (GCAP3), whose function in vitro is nearly identical to GCAP1, is expressed specifically in human cones (41, 42) . Though the relative contribution of GCAP3 to human cone physiology is undefined, redundancy of GCAPs in human may compensate for effects caused by down-regulation of GCAP1, and therefore sustain bright light (photopic) vision.
